Surveyed Neurologists in Both the United States and Europe Indicate That a Once-Daily Transdermal Formulation of Levodopa Would Earn a 30 Percent Patient Share in Parkinson's Disease
Posted on: Tuesday, 28 April 2009, 07:00 CDT
Stalevo Will Retain Decision Resources' Gold-Standard Status Through 2017 for Parkinson's Disease, According to a New Report from Decision Resources
The new report entitled Parkinson's Disease: A Transdermal Formulation of Levodopa Would Tap into a Significant Opportunity in This Mature Market also finds that surveyed neurologists identify a therapy's effect on levodopa-induced motor response complications as one of the key attributes that strongly influences their prescribing decisions in Parkinson's disease.
In 2008, Decision Resources' proprietary clinical gold standard for Parkinson's disease was Novartis/Orion Pharma's Stalevo. Based on available data and expert opinion, Stalevo will retain gold standard status through 2017, owing to its safety and efficacy when compared to other available agents in the market. Interviewed thought leaders indicate that Stalevo has efficacy advantages over the immediate-release formulation of Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol.
"In particular, Stalevo scores higher on each of the top three efficacy metrics weighted by surveyed neurologists as the most influential in their choice of a Parkinson's disease therapy," said Decision Resources Analyst
About the Report
Parkinson's Disease: A Transdermal Formulation of Levodopa Would Tap into a Significant Opportunity in This Mature Market is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 ccomfort@dresources.com emarshall@dresources.comSOURCE Decision Resources
Source: PR Newswire
Related Articles
- Growth in the Parkinson's Disease Drug Market, Fueled by the Launch of Several New Therapies, Will be Offset by Generic Erosion of Key Agents
- Parkinson's Disease Market Upgrade Following Evidence of Disease Slowing With Azilect
- Research and Markets: Out Now - CNS Drug Discoveries: Parkinson's Disease Chapter
- Generic Erosion of Market Leading Therapies Will Constrain Growth in the Parkinson's Disease Drug Market Over the Next Decade
- Depression in Parkinsons Disease Has Both Psychological and Pathological Causes
- Levodopa Remains the Best at Treating Parkinson's Disease As There Are Few Drugs That Match Its Success
- Initiation of Largest Disease Modification Trial to Study Effect of AGILECT(R) in Slowing Progression of Parkinson's Disease
- Avigen Announces Encouraging Early Data From Parkinson's Disease Clinical Trial
- Study Showed AGILECT(R) Improved Motor Fluctuations and Parkinson's Disease Symptoms in Levodopa-Treated Patients
 |
 |
User Comments (0)
RSS Feeds